AR005416A1 - Un compuesto de (5r, 6s)-2-[1-etil-5-metilpirazol-3-il]-6-[(1r)-1- hidroxietil]-carbapen-2-em-3-carboxilato, un procedimiento para prepararlo, unacomposicion farmaceutica que lo contiene y el uso de dicho compuesto para la fabricacion de un medicamento para tratar infecciones bacterianas - Google Patents
Un compuesto de (5r, 6s)-2-[1-etil-5-metilpirazol-3-il]-6-[(1r)-1- hidroxietil]-carbapen-2-em-3-carboxilato, un procedimiento para prepararlo, unacomposicion farmaceutica que lo contiene y el uso de dicho compuesto para la fabricacion de un medicamento para tratar infecciones bacterianasInfo
- Publication number
- AR005416A1 AR005416A1 ARP960102434A AR10243496A AR005416A1 AR 005416 A1 AR005416 A1 AR 005416A1 AR P960102434 A ARP960102434 A AR P960102434A AR 10243496 A AR10243496 A AR 10243496A AR 005416 A1 AR005416 A1 AR 005416A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- bacterial infections
- carbapen
- carboxylate
- hydroxyethyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 208000035143 Bacterial infection Diseases 0.000 title abstract 3
- 208000022362 bacterial infectious disease Diseases 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- -1 isobutyryloxymethyl Chemical group 0.000 abstract 3
- CWSOMYSZKNMLHZ-GGZOMVNGSA-N (5r,6s)-3-(1-ethyl-5-methylpyrazol-3-yl)-6-[(1r)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid Chemical compound C1=C(C)N(CC)N=C1C1=C(C(O)=O)N2C(=O)[C@H]([C@@H](C)O)[C@H]2C1 CWSOMYSZKNMLHZ-GGZOMVNGSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
- C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
- C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
- C07D477/14—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
- C07D477/02—Preparation
- C07D477/06—Preparation from compounds already containing the ring or condensed ring systems, e.g. by dehydrogenation of the ring, by introduction, elimination or modification of substituents
- C07D477/08—Modification of a carboxyl group directly attached in position 2, e.g. esterification
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se refiere a un nuevo compuesto de (5R,6S)-2-[1-etil-5-metilpirazol-3-il] -6-[(1R)-1-hidroxietil]-carbapen-2-em-3-carboxilato de fórmula (I), en la queR se selecciona entre el grupo formado por isobutiriloximetilo, (5-metil-2-oxo- 1,3-dioxolen-4-il)metilo y benzoiloximetilo es útil en el tratamiento deinfecciones bacterianas. También se refiere a un procedimiento para prepararlo, a una composición farmacéutica que lo contiene y al uso de dicho compuesto parala publicación de un medicamento para tratar infecciones bacterianas.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9508956.1A GB9508956D0 (en) | 1995-05-03 | 1995-05-03 | Novel compounds |
| GBGB9508955.3A GB9508955D0 (en) | 1995-05-03 | 1995-05-03 | Novel compounds |
| GBGB9508957.9A GB9508957D0 (en) | 1995-05-03 | 1995-05-03 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR005416A1 true AR005416A1 (es) | 1999-06-23 |
Family
ID=27267696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP960102434A AR005416A1 (es) | 1995-05-03 | 1996-05-03 | Un compuesto de (5r, 6s)-2-[1-etil-5-metilpirazol-3-il]-6-[(1r)-1- hidroxietil]-carbapen-2-em-3-carboxilato, un procedimiento para prepararlo, unacomposicion farmaceutica que lo contiene y el uso de dicho compuesto para la fabricacion de un medicamento para tratar infecciones bacterianas |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP0823910A1 (es) |
| JP (1) | JPH11504910A (es) |
| KR (1) | KR19990008355A (es) |
| CN (1) | CN1185783A (es) |
| AR (1) | AR005416A1 (es) |
| AU (1) | AU5813996A (es) |
| BG (1) | BG102014A (es) |
| BR (1) | BR9608313A (es) |
| CA (1) | CA2217990A1 (es) |
| CZ (1) | CZ347597A3 (es) |
| EA (1) | EA199700293A1 (es) |
| HU (1) | HUP9801066A3 (es) |
| IL (1) | IL118092A0 (es) |
| MA (1) | MA23853A1 (es) |
| MX (1) | MX9708421A (es) |
| NO (1) | NO974994L (es) |
| OA (1) | OA10632A (es) |
| PE (1) | PE50697A1 (es) |
| PL (1) | PL323141A1 (es) |
| SK (1) | SK146497A3 (es) |
| TR (1) | TR199701286T1 (es) |
| WO (1) | WO1996034868A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2902659A1 (fr) | 2006-06-23 | 2007-12-28 | Pierre Fabre Medicament Sa | Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires |
| WO2013157583A1 (ja) * | 2012-04-18 | 2013-10-24 | 大日本住友製薬株式会社 | 新規カルバペネム化合物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1593524A (en) * | 1976-11-19 | 1981-07-15 | Merck & Co Inc | 1-carba-2-penem-3-carboxylic acids |
| CA1212105A (en) * | 1980-04-30 | 1986-09-30 | Shoji Ikeda | Ampicillin esters and production thereof |
| WO1995005380A1 (en) * | 1993-08-18 | 1995-02-23 | Sankyo Company, Limited | Crystalline carbapenem derivatives |
| SK53696A3 (en) * | 1993-10-29 | 1996-10-02 | Smithkline Beecham Plc | Carbapenem derivatives, their preparation, pharmaceutical compositions containing them and their use |
-
1996
- 1996-05-01 IL IL11809296A patent/IL118092A0/xx unknown
- 1996-05-02 WO PCT/EP1996/001880 patent/WO1996034868A1/en not_active Ceased
- 1996-05-02 CN CN96194191A patent/CN1185783A/zh active Pending
- 1996-05-02 JP JP8533020A patent/JPH11504910A/ja active Pending
- 1996-05-02 MX MX9708421A patent/MX9708421A/es unknown
- 1996-05-02 KR KR1019970707881A patent/KR19990008355A/ko not_active Withdrawn
- 1996-05-02 EA EA199700293A patent/EA199700293A1/ru unknown
- 1996-05-02 PL PL96323141A patent/PL323141A1/xx unknown
- 1996-05-02 SK SK1464-97A patent/SK146497A3/sk unknown
- 1996-05-02 HU HU9801066A patent/HUP9801066A3/hu unknown
- 1996-05-02 AU AU58139/96A patent/AU5813996A/en not_active Abandoned
- 1996-05-02 CZ CZ973475A patent/CZ347597A3/cs unknown
- 1996-05-02 MA MA24218A patent/MA23853A1/fr unknown
- 1996-05-02 EP EP96919678A patent/EP0823910A1/en not_active Withdrawn
- 1996-05-02 CA CA002217990A patent/CA2217990A1/en not_active Abandoned
- 1996-05-02 TR TR97/01286T patent/TR199701286T1/xx unknown
- 1996-05-02 BR BR9608313A patent/BR9608313A/pt not_active Application Discontinuation
- 1996-05-03 PE PE1996000312A patent/PE50697A1/es not_active Application Discontinuation
- 1996-05-03 AR ARP960102434A patent/AR005416A1/es unknown
-
1997
- 1997-10-30 NO NO974994A patent/NO974994L/no not_active Application Discontinuation
- 1997-11-03 BG BG102014A patent/BG102014A/xx unknown
- 1997-11-03 OA OA70122A patent/OA10632A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL118092A0 (en) | 1996-09-12 |
| CN1185783A (zh) | 1998-06-24 |
| WO1996034868A1 (en) | 1996-11-07 |
| BG102014A (en) | 1998-11-30 |
| EA199700293A1 (ru) | 1998-06-25 |
| HUP9801066A2 (hu) | 1998-08-28 |
| HUP9801066A3 (en) | 1999-01-28 |
| SK146497A3 (en) | 1998-05-06 |
| PE50697A1 (es) | 1997-12-18 |
| CZ347597A3 (cs) | 1998-08-12 |
| BR9608313A (pt) | 1999-01-26 |
| MA23853A1 (fr) | 1996-12-31 |
| MX9708421A (es) | 1998-02-28 |
| CA2217990A1 (en) | 1996-11-07 |
| NO974994D0 (no) | 1997-10-30 |
| PL323141A1 (en) | 1998-03-16 |
| JPH11504910A (ja) | 1999-05-11 |
| NO974994L (no) | 1997-10-30 |
| AU5813996A (en) | 1996-11-21 |
| KR19990008355A (ko) | 1999-01-25 |
| TR199701286T1 (xx) | 1998-02-21 |
| OA10632A (en) | 2002-09-16 |
| EP0823910A1 (en) | 1998-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI232219B (en) | Compounds containing cyclohexane group, process for preparing them and pharmaceutical composition containing them | |
| BR0114321A (pt) | Composto, composição farmacêutica, uso de um composto, método de tratamento ou profilaxia de doenças inflamatórias, e, processo para preparar um composto | |
| BR0317358A (pt) | Composto de pirrolopiridazina, processo para sua preparação, composição farmacêutica contendo o mesmo, método de prevenção ou tratamento de doenças contendo o mesmo e seu uso | |
| GEP20001940B (en) | Valaciclovir Hydrochloride in Essentially Anhydrous Crystalline Form, Processes for its Producing, Use and Method of Treatment | |
| EE03253B1 (et) | (R)-5-karbamoüül-8-fluoro-3-N,N-diasendatud-amino-3,4-dihüdro-2H-1-bensopüraani d, nende valmistamise protsess ja neid sisaldavad ravimkoostised | |
| BR0309875A (pt) | métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto | |
| WO2003070163A3 (en) | Prostacyclin derivatives for treating cancer | |
| PL307914A1 (en) | Lipopetide derivatives, method of obtaining them and therapeutic agents containing such compounds | |
| AR019496A1 (es) | Azalidas de 13 miembros, composiciones farmaceuticas, uso en la preparacion de medicamentos y preparacion de los mismos | |
| BR0112330A (pt) | Formulações de macrolìdeos para inalação e seus usos para o tratamento de infecções endobrÈnquicas | |
| ES2160643T3 (es) | Composiciones que contienen g-csf y proteina de union al tnf. | |
| GEP20012389B (en) | Benzoxazinone Dopamine D4 Receptor Antagonists, Pharmaceutical Composition Containing the Same and Method for Treatment of Psychosis or Schizophrenia | |
| EP1608655B8 (en) | Pyrroloimidazole derivatives, their preparation, pharmaceutical compositions containing them, and their use as nootropic agents | |
| BR9814498A (pt) | Processo para o tratamento de obesidade em um humano necessitando de tal tratamento, composto, uso do mesmo, produto, e, composição farmacêutica | |
| AP9300561A0 (en) | Antibiotic compounds. | |
| AR005416A1 (es) | Un compuesto de (5r, 6s)-2-[1-etil-5-metilpirazol-3-il]-6-[(1r)-1- hidroxietil]-carbapen-2-em-3-carboxilato, un procedimiento para prepararlo, unacomposicion farmaceutica que lo contiene y el uso de dicho compuesto para la fabricacion de un medicamento para tratar infecciones bacterianas | |
| NZ324380A (en) | Therapeutic benzimidazole compounds and their use in treatment of virus infections | |
| BR0006301A (pt) | Macrólidos antibacterianos e pró-cinéticos | |
| BR0308837A (pt) | Composto, composição, método e medicamento para o tratamento de infecções bacterianas, psorìase ou artrite em mamìferos, método e medicamento para o tratamento de toxicidade devido a quimioterapia em um paciente, composição farmacêutica, processo para a preparação de um composto e processo para a conversão dos compostos da fórmula (i) em compostos adicionais da fórmula (i) | |
| NZ332453A (en) | (1R,5S,6S)-6-[(1R)-1-hydroxyethyl]-1-methyl-2-[(2S,4S)-2-[(3R)-3-methylaminomethylpyrrolidin-1-ylcarbonyl]pyrrolidin-4-ylthio]-1-carbapen-2-em-3-carboxylic acid for the prevention or treatment of bacterial infections | |
| RU94041028A (ru) | Применение производных мелатонина для лечения десинхронизационных нарушений, фармацевтическая композиция | |
| AU3020492A (en) | New pyrrolidine compounds, process for preparing them and pharmaceutical compositions containing them | |
| CO4750657A1 (es) | Nuevos compuestos | |
| AR008605A1 (es) | Procedimiento para preparar clavulanato de potasio, clavulanato de potasio en la forma de estrellas reventadas a modo de rosetas cristalinas, unacomposicion farmaceutica que lo contiene, el uso del mismo para la preparacion de un medicamento para tratar infecciones bacterianas. | |
| AU7869087A (en) | Method of promoting wound-healing |